Abstracts tagged "autoimmune diseases"

Abstract Number: 0717 • ACR Convergence 2022
Treatment Utilization in Dermatomyositis: An Analysis of Electronic Medical Records in the United States
Adrian Kielhorn¹, Zheng Wang¹, Kristin Moy¹, Lisa Christopher-Stine², Ingrid Lundberg³, Hector Chinoy⁴, Kaniah Gunter⁵ and Rohit Aggarwal⁶, ¹Alexion, AstraZeneca Rare Disease, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁴The University of Manchester, Sale, United Kingdom, ⁵Patient Author, Norfolk, VA, ⁶Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Dermatomyositis (DM) is a rare, chronic inflammatory disease characterized by skin manifestations and/or progressive muscle weakness and other systemic manifestations. Patients with DM were…
Abstract Number: 0772 • ACR Convergence 2022
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
Carina Soto-Fajardo¹, Angélica Peña Ayala², Fernanda Gonzalez², Paola Flores², Ana Cristina Medina², Araceli Bernal², Carlos Pineda², Olga-Lidia Vera-Lastra³ and Luis Javier Jara Quezada², ¹Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ³Centro Médico La Raza, Ciudad de México, Mexico
Background/Purpose: From January 2021 around 60% of the total population has received at least one dose of any COVID-19 vaccine. A minority of vaccinated individuals…
Abstract Number: 0935 • ACR Convergence 2022
Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
Giorgio CASABURI, Tyler O'Malley, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity. RA affects approximately 0.5/1% of adults in the…
Abstract Number: 1142 • ACR Convergence 2022
The Lupus Risk Allele Associated Xq28 Haplotype Identifies the Molecular Endotype of a Cohort of European SLE Patients with Enhanced IRAK1 Signaling
Rheyanna Clemens¹, Tyson Dawson¹, Katherine Owen², Amrie Grammer³ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²RILITE, Crozet, VA, ³AMPEL LLC, Charlottesville, VA
Background/Purpose: Previous genetic association studies identified a 9 gene region of Xq28 containing IRAK1 as a risk locus for SLE. IRAK1 plays key roles downstream…
Abstract Number: 1347 • ACR Convergence 2022
Poor Health-Related Quality of Life in Patients with Lupus Nephritis
Cristina Arriens¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) associated with considerable morbidity that has a devastating impact…
Abstract Number: 1629 • ACR Convergence 2022
AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases
Shawn Morales, Jennifer Cross and Robert Huizinga, Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada
Background/Purpose: AUR200 targets both B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key mediators in the pathogenesis of B cell-mediated autoimmune…
Abstract Number: 1836 • ACR Convergence 2022
Schizophrenia and Its Relationship with Autoimmunity: A Nationwide Analysis
Faria Sami¹, Dennis Kumi¹, Sumbul Liaqat² and Hania Sami³, ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Shalamar Medical and Dental College, Chicago, IL
Background/Purpose: It has been hypothesized that autoimmunity may play a role in the pathophysiology of schizophrenia (SCZ). Several autoimmune disorders (AID) have also been noted…
Abstract Number: 2182 • ACR Convergence 2022
mRNA Vaccine Against Fibroblast Activation Protein Ameliorates Murine Models of Inflammatory Arthritis
Xiaowei Zhang¹, Antony Jozic¹, Pingfang Song¹, Qiang Xu², Xiaofei Shi³, Hong Wang⁴, Lindsey Bishop¹, Hillary Struthers¹, John Rutledge⁵, Shuang Chen¹, Fei Xu¹, Meaghan Hancock¹, Daocheng Zhu⁶, Gaurav Sahay¹ and Cong-Qiu Chu¹, ¹Oregon Health & Science University, Portland, OR, ²Guangzhou University of Chinese Medicine, Guangzhou, China, ³Henan University of Science and Technology, Luoyang, China, ⁴Wenzhou Medical University, Wenzhou, China, ⁵Portland VA Research Foundation, Portland, ⁶Shanghai Kexin Biotechnology, Shanghai, China
Background/Purpose: Synovial fibroblasts in patients with rheumatoid arthritis (RA) contribute substantially to the perpetuation of synovitis and invasion to cartilage and bone, and have been…
Abstract Number: PP23 • ACR Convergence 2022
The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY
Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
Abstract Number: 0008 • ACR Convergence 2022
CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow
Jennifer Barnas¹, Diana Alzamareh², Nida Meednu² and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: CD11c+ age/autoimmunity-associated B cells (ABC) are associated with autoantibody producing cells and disease flare in systemic lupus erythematosus. ABC were initially identified in aged…
Abstract Number: 0140 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Müller⁶, Carl Coeck⁷, Klaus Rohr⁸ and Wim Wuyts⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim SComm, Brussels, Brussels, Belgium, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital…
Abstract Number: 0359 • ACR Convergence 2022
Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
Ronald Van Vollenhoven¹, Eric F. Morand², Richard A. Furie³, Ian N. Bruce⁴, Gabriel Abreu⁵, Raj Tummala⁶, Hussein Al-Mossawi⁷ and Catharina Lindholm⁸, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, University of Amsterdam, Amsterdam, Netherlands, ²Monash University, Melbourne, Australia, ³Northwell Health, Great Neck, NY, ⁴The University of Manchester, Manchester, United Kingdom, ⁵AstraZeneca, Mölndal, Sweden, ⁶AstraZeneca, Gaithersburg, MD, ⁷AstraZeneca, Cambridge, United Kingdom, ⁸AstraZeneca, Gothenburg, Sweden
Background/Purpose: In patients with SLE, achieving remission is a treat-to-target goal. Remission is associated with lower rates of hospitalization and damage accrual and better quality…
Abstract Number: 0637 • ACR Convergence 2022
Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals
Carolina Munoz¹, Sindu Johnson², Zahi Touma¹, Zareen Ahmad², Dennisse Bonilla¹, Linda Hiraki³, Arthur Bookman² and Joan Wither⁴, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Currently the immune changes that lead to the transition from asymptomatic Anti-Nuclear Antibody (ANA) positivity to symptomatic disease are unknown. Studies in our laboratory…
Abstract Number: 0721 • ACR Convergence 2022
Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex
Ashley Archer¹, Ruth Topless², Angelo Gaffo¹, Nicola Dalbeth³, Lisa Stamp⁴, Philip Robinson⁵ and Tony Merriman², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵School of Clinical Medicine, University of Queensland, Brisbane, Australia
Background/Purpose: There is increasing evidence that rheumatoid arthritis (RA) is a risk factor for death related to COVID-19, however data on the risk of death…
Abstract Number: 0781 • ACR Convergence 2022
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Daniel Magliulo¹, Vasileios Kyttaris¹ and Emily Rose², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, West Roxbury, MA
Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].